The combination of lenvatinib and pembrolizumab is based on a strong mechanistic rationale with immunomodulatory properties: increased tumor infiltration of effector CD8+ T cells and decreased monocytes and macrophages [14]. The gene discussed is CD8A; the disease is neoplasm.